Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies

Int J Biol Sci. 2022 Aug 21;18(14):5369-5390. doi: 10.7150/ijbs.73949. eCollection 2022.

Abstract

The incidence of cholangiocarcinoma (CCA) has been increasing over the past few years. Although there are surgery, chemotherapy and other conventional treatment methods, the effect is not as expected. At present, immunotherapy has become the research frontier of cancer treatment, and CCA tumor microenvironment (TME) is becoming a hot exploration direction of immunobiology. TME can affect tumor progression through changes in metabolism, secretion and immunity. Accordingly, understanding the role played by immune cells and stromal cells in TME is important for the study of CCA immunotherapy. This review will discuss the interactions between immune cells (including CD8+ T cells, CD4+ T cells, macrophages, natural killer cells, dendritic cells, myeloid suppressor cells, mast cells, and neutrophils) and stromal cells (including cancer-associated fibroblasts, endothelial cells) in the TME of CCA. In addition, we will also discuss current research results on TME of CCA and recent advances in immunotherapy.

Keywords: cholangiocarcinoma; immune mechanism; immunotherapy; prognostic markers; targeted therapy; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bile Duct Neoplasms* / pathology
  • Bile Duct Neoplasms* / therapy
  • Bile Ducts, Intrahepatic / metabolism
  • Bile Ducts, Intrahepatic / pathology
  • CD8-Positive T-Lymphocytes
  • Cholangiocarcinoma* / pathology
  • Cholangiocarcinoma* / therapy
  • Endothelial Cells / metabolism
  • Humans
  • Immunotherapy
  • Neoplasms* / metabolism
  • Tumor Microenvironment